Analyst firms · H.C. Wainwright · CAPR

H.C. Wainwright CAPR price target and rating history

Capricor Therapeutics Inc. (CAPR) · Health Care

H.C. Wainwright rates Capricor Therapeutics Inc. (CAPR) Neutral with a $18 price target, as of its latest action on Jul 30, 2026. It has published 3 rating actions on CAPR since October 2021, including 0 upgrades and 1 downgrade. Across 6 firms with a CAPR price target in the last 12 months, the median target is $23.

Current rating

Neutral

Price target

$18

Median target, all firms

$23

Actions on CAPR

3

H.C. Wainwright price target on CAPR

Every H.C. Wainwright rating on CAPR

• Jul 30, 2026
  DowngradeH.C. Wainwright downgrades to Neutral from Buy
• Jan 31, 2022
  ReiterateH.C. Wainwright raises its price target to $18 from $14, keeps Buy
• Oct 11, 2021
  ReiterateH.C. Wainwright raises its price target to $14 from $9, keeps Buy

How other firms rate CAPR

Each firm's latest rating and stated target in the last 12 months.

Questions about H.C. Wainwright and CAPR

What is H.C. Wainwright's price target for CAPR?

H.C. Wainwright's latest stated price target for Capricor Therapeutics Inc. (CAPR) is $18, from its action on Jan 31, 2022.

What is H.C. Wainwright's rating on CAPR?

H.C. Wainwright rates CAPR Neutral, a neutral rating, as of Jul 30, 2026.

When did H.C. Wainwright last change its view on CAPR?

On Jul 30, 2026, H.C. Wainwright downgrades to Neutral from Buy.

How does H.C. Wainwright's CAPR target compare with other analysts?

Across 6 firms with a CAPR price target in the last 12 months, the median target is $23.

More CAPR rating histories

• B. Riley Securities3
• Piper Sandler3
• Oppenheimer3
• Cantor Fitzgerald3

All H.C. Wainwright ratingsCAPR news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.